Poe Brandon reported option exercise involving 2,699 shares of BioStem Technologies, Inc. at $0.00 for $0 on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
2,699Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
60,763Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:30 PM ET2-day reporting delay
Accession
0001193125-26-460770Code M · Transaction 400762
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise2,699$0.00$0Trade 400763
2 transaction rows in this filing. Joint filers share the same rows.

BSEM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BSEM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +132%1w ago +8.6%1d ago −1%
Returns since7d30d90d180d1y

Footnotes in full

F1: Reflects an adjustment to total holdings to include two shares incorrectly excluded in prior reports. F2: These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period. F3: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5: These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024). F6: These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. F7: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.